NEW YORK, Jan. 28, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Tetraphase Pharmaceuticals Inc. (“Tetraphase”) (NASDAQ:TTPH) between March 5, 2015 and September 8, 2015. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of Massachusetts. To get more information go to:
http://zlk.9nl.com/tetraphase-pharmaceuticals-ttph
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that Tetraphase and certain insiders issued materially false and misleading statements to investors. In particular, it is alleged that throughout the class period, Tetraphase made positive statements about the efficacy and potential for its drug Eravacycline to achieve approval by the FDA, despite knowledge that a pivotal portion of its IGNITE2 phase 3 clinical trial for Eravacycline would fail to achieve its primary endpoint of statistical non-inferiority compared to the antibiotic Levofloxacin.
On September 8, 2015, the Company announced that the pivotal portion of its IGNITE2 phase 3 clinical trial of Eravacycline did not achieve its primary endpoint. Following this news, shares of Tetraphase fell from a close of $44.78 on September 8, 2015, to a close of $8.36 per share on September 10, 2015—a loss of more than 80% in market value.
If you suffered a loss in Tetraphase you have until March 28, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback
Sodexo Unveils Shift & Grow 2030 Strategy, Targets Over 5% Revenue Growth by Fiscal 2030
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates
Jamie Dimon Warns Anthropic's Mythos AI Poses National Security Risks
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters
UBS Boosts China Tech Bets, Adds Kuaishou and Meituan to Focus List
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States
SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 



